A Study Evaluating the Safety and Efficacy of IBI188 in Combination With AZA in Subjects With Newly Diagnosed MDS

Main Inclusion Criteria: 1. Newly diagnosed MDS subjects with higher risk. 2. Age ≥ 18 years old. 3. Eastern Cooperative Oncology Group score of 0-2. 4. Adequate organ function. 5. Subjects should take effective contraceptive measures. 6. Must sign the Informed Consent Form (ICF), and be able to follow all study procedures. Main Exclusion Criteria: 1. Subject who has transformed from MDS to AML. 2. MDS subjects with lower risk. 3. Subjects who have received chemotherapy. 4. History of chronic hemolytic anemia 5. Prior exposure to any anti-CD47 or anti-SIRPα agents. 6. Subjects participating in another interventional clinical study.